Bakuchiol

Plant-derived retinoid alternative from Psoralea corylifolia with dual value in brightening formulations through modest direct tyrosinase inhibition and retinol-like keratinocyte turnover promotion. A 2024 systematic review of 15 clinical trials confirmed efficacy for post-inflammatory hyperpigmentation, aging, and acne with good tolerability. Bakuchiol functions best as a complementary ingredient alongside primary tyrosinase inhibitors rather than as a standalone brightening active. Key advantages versus retinoids include no photosensitization, pregnancy compatibility, and exemption from EU 2024/996 Vitamin A concentration restrictions, making it excellent for sensitive skin and darker phototypes.

No FDA restrictions. Not a retinoid and not subject to OTC drug classification for retinoids. No concentration restrictions. Safety supported by botanical extract precedent and growing clinical trial database.